Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 3/20 | 0.63 |
| ▸ | KDR | P35968 | 5/20 | 0.60 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31039816 | 1.00 | LCK (0.63) | LCKKDRMAPK13MAPK12MAPK11 | |
| SCHEMBL4252563 | 0.81 | MAPK14 (0.74) | KDRMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL774811 | 0.78 | LCK (1.00) | LCKKDRMAPK13MAPK12MAPK11 | |
| SCHEMBL525976 | 0.78 | KDR (0.58) | LCKKDRMAPK13MAPK12MAPK11 | |
| SCHEMBL27950830 | 0.77 | MAPK14 (0.57) | MAPK13MAPK12MAPK11MAPK14ALDH1A1 | |
| SCHEMBL772868 | 0.76 | LCK (1.00) | LCKKDRMAPK13MAPK12MAPK11 | |
| SCHEMBL19205380 | 0.75 | LCK (0.43) | LCKKDRMAPK13MAPK12MAPK11 | |
| SCHEMBL6179920 | 0.75 | KDR (1.00) | LCKKDR | |
| SCHEMBL4250552 | 0.75 | KDR (0.59) | LCKKDRMAPK13MAPK12MAPK11 | |
| SCHEMBL2491213 | 0.75 | RAB9A (0.54) | MAPK13MAPK12MAPK11MAPK14ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | claimed |
| EP-1841431-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-10-10 | — | — | EP | claimed |
| WO-2006081172-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-08-03 | — | — | WO | claimed |
| US-12325702-B2 | ATF6 inhibitors and uses thereof | ALTOS LABS, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20240124434-A1 | ATF6 INHIBITORS AND USES THEREOF | ALTOS LABS, INC. | 2024-04-18 | — | — | US | disclosed |
| US-20210221803-A1 | ATF6 INHIBITORS AND USES THEREOF | ALTOS LABS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210221803-A1 | ATF6 INHIBITORS AND USES THEREOF | ALTOS LABS, INC. | 2021-07-22 | — | — | US | disclosed |
| EP-3774782-A2 | ATF6 INHIBITORS AND USES THEREOF | Black Belt TX Ltd (GB) | 2021-02-17 | — | — | EP | disclosed |
| CN-112313224-A | ATF6 inhibitors and uses thereof | 黑带医疗有限责任公司 | 2021-02-02 | — | — | CN | disclosed |
| US-10829485-B2 | ATF6 inhibitors and uses thereof | BLACK BELT TX LTD (GB) | 2020-11-10 | — | — | US | disclosed |
| US-10829485-B2 | ATF6 inhibitors and uses thereof | BLACK BELT TX LTD (GB) | 2020-11-10 | — | — | US | disclosed |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
| EP-1841431-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006081172-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124434-A1 | ATF6 INHIBITORS AND USES THEREOF | ATF4, XBP1, ATF1 | LCK 3014/4885KDR 3109/4885MAPK13 408/4885 |
| US-12325702-B2 | ATF6 inhibitors and uses thereof | ATF4, XBP1, ATF1 | LCK 3014/4885KDR 3109/4885MAPK13 408/4885 |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ABL1, BCR, PDGFRB | LCK 56/4885KDR 172/4885MAPK13 392/4885 |
| US-10829485-B2 | ATF6 inhibitors and uses thereof | ATF4, XBP1, ATF1 | LCK 3014/4885KDR 3109/4885MAPK13 408/4885 |
| US-20210221803-A1 | ATF6 INHIBITORS AND USES THEREOF | ATF4, XBP1, ATF1 | LCK 3014/4885KDR 3109/4885MAPK13 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.